Skip to content
Screener

Vaxcyte, Inc. PCVX Total Liabilities

Total Liabilities at other companies

Pfizer logo
PfizerPFE
$3.41B-97.1%
Merck & Co. logo
Merck & Co.MRK
$229M
Moderna logo
ModernaMRNA
$4.2B+60.9%
Novavax logo
NovavaxNVAX
$1.15B-11.8%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$120.24M+34.0%
Regenxbio logo
RegenxbioRGNX
$314.85M-14.3%

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$8.07B+89.7%
Enterprise value$7.93B+96.5%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001649094-26-000017
Line itemMarch 31,2026December 31, 2025
Operating lease liabilities — current6,0856,124
Total current liabilities242,082205,750
Operating lease liabilities — long-term110,212111,457
Total liabilities352,294317,207
Commitments and contingencies (Note 6)
Stockholders' Equity
Preferred stock, $0.001 par value — 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.001 par value — 500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 144,314,981 and 131,058,858 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively147134

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Vaxcyte, Inc.'s total liabilities?
Vaxcyte, Inc. (PCVX) reported total liabilities of $352.29M in Q1 2026.
How has Vaxcyte, Inc.'s total liabilities changed year-over-year?
Vaxcyte, Inc.'s total liabilities increased by 97.8% year-over-year, from $178.08M to $352.29M.
What is the long-term trend for Vaxcyte, Inc.'s total liabilities?
Over 5 years (2020 to 2025), Vaxcyte, Inc.'s total liabilities has grown at a 46.5% compound annual growth rate (CAGR), from $46.98M to $317.21M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Vaxcyte, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude